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Abstract
Background: HIV disproportionately affects African-Caribbean women in Canada but the frequency and distribution
of sexually transmitted infections in this community have not been previously studied.
Methods: We recruited women based on HIV status through a Toronto community health centre. Participants
completed a socio-behavioural questionnaire using Audio Computer Assisted Self-Interview (ACASI) and provided
blood for syphilis, HIV, hepatitis B and C, herpes simplex virus type 1 (HSV-1), herpes simplex virus type 2 (HSV-2),
and human cytomegalovirus (CMV) serology, urine for chlamydia and gonorrhea molecular testing and vaginal
secretions for bacterial vaginosis (BV) and human papillomavirus (HPV). Differences in prevalence were assessed for
statistical significance using chi-square.
Results: We recruited 126 HIV-positive and 291 HIV-negative women, with a median age of 40 and 31 years,
respectively (p < 0.001). Active HBV infection and lifetime exposure to HBV infection were more common in
HIV-positive women (4.8% vs. 0.34%, p = 0.004; and 47.6% vs. 21.2%, p < 0.0001), as was a self-reported history of
HBV vaccination (66.1% vs. 44.0%, p = 0.0001). Classical STIs were rare in both groups; BV prevalence was low and
did not vary by HIV status. HSV-2 infection was markedly more frequent in HIV-positive (86.3%) than HIV-negative
(46.6%) women (p < 0.0001). Vaginal HPV infection was also more common in HIV-positive than in HIV-negative
women (50.8% vs. 22.6%, p < 0.0001) as was infection with high-risk oncogenic HPV types (48.4% vs. 17.3%,
p < 0.0001).
Conclusions: Classical STIs were infrequent in this clinic-based population of African-Caribbean women in Toronto.
However, HSV-2 prevalence was higher than that reported in previous studies in the general Canadian population
and was strongly associated with HIV infection, as was infection with hepatitis B and HPV.
Keywords: Sexually transmitted infections, HIV, Epidemiology, African-Caribbean women, Toronto
Background
In 2011, 34 million people worldwide were infected with
HIV and 1.7 million died [1]. Most HIV transmission is
sexual and it is increasingly clear that common sexually
transmitted bacterial and viral co-infections contribute
significantly to HIV transmission risk and disease pro-
gression [2]. Infections that appear to enhance suscepti-
bility and infectivity through sexual transmission include
herpes simplex virus type 2 (HSV-2), human papilloma
virus (HPV), syphilis, gonorrhea, vaginal candidiasis, geni-
tal chlamydia and bacterial vaginosis (BV) [2-4]. HSV-2,
human cytomegalovirus (CMV) and viral hepatitis B and
C have been linked to more rapid disease progression
and increased mortality [5-8]. Therefore, a better under-
standing of the epidemiology of these co-infections in
HIV-affected communities is important.
Sub-Saharan Africa has a disproportionately high preva-
lence of both HIV and several genital co-infections that
have been associated with increased HIV transmission,
most notably HSV-2 and HPV [9-12]. Furthermore,
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African and Caribbean communities in North America
and Europe have also been disproportionately affected by
HIV [3], and HSV-2 infection is also very common [13].
HIV infection is frequent in African and Caribbean
women in Ontario [14], with a rate 24-fold greater than
other women [3]. Therefore, we aimed to characterize the
epidemiology of HIV and other sexually transmitted infec-
tions (STIs) in African-Caribbean (AC) women in Toronto




The study population consisted of women 16 years of
age or older from Africa and the Caribbean living in
Greater Toronto. Women were eligible if they self-
identified as African or Caribbean and if they, a parent
or grandparent were born in sub-Saharan Africa or the
Caribbean. We recruited women attending the Women’s
Health in Women’s Hands Community Health Centre for
medical care or on-site support groups from April 2009 to
October 2010. We also recruited some participants from
affiliated women’s shelters. Since we aimed to assess the
possible associations of co-infections with HIV infec-
tion, we recruited both HIV-positive and HIV-negative
attendees, with over-sampling of the former. We aimed
therefore to recruit 300 HIV-negative and 300-HIV-positive
women. The sample size was selected to maximize preci-
sion of STI prevalence estimates and for feasibility consid-
erations. The study protocol was approved by the Health
Research Ethics Board of the University of Toronto.
Participants completed a self-administered questionnaire
using ACASI (Audio Computer Assisted Self-Interview),
(Questionnaire Development System (QDS) Version 2.5,
Nova Research Company, Bethesda, Maryland, USA) and
provided biologic specimens. The questionnaire included
demographic information, sexual behaviour (in the previ-
ous six months and lifetime, number of sexual partners
and condom usage), history of STIs and other medical
conditions.
Sample collection
After informed consent, we collected 20 ml of blood by
venipuncture. Participants provided a first-void urine spe-
cimen and self-collected vaginal swab for HPV molecular
diagnostics. For this purpose, participants inserted the
swab into the vaginal vault and inserted it into a collection
tube containing transport medium. Vaginal specimens for
Gram stain were collected as described by Boskey [15].
Laboratory methods
HIV testing was performed on serum by enzyme immuno-
assay (EIA; AxSYM HIV 1/2 gO, Abbott Diagnostics
Division, Wiesbaden, Germany). If reactive, the EIA was
repeated and confirmed at the Ontario Public Health
Laboratory by Ag/Ab testing (Architect Ag/Ab Combo,
Abbott Diagnostics, Abbott Park, IL, USA) and by
Western blot. Serologic testing was also performed for
herpes simplex, types 1 and 2 (Herpes Simplex Virus
ELISA IgG, Focus Diagnostics, Cypress, CA, USA); human
cytomegalovirus (CMV; AxSYM CMV IgG; Abbott Diag-
nostics Division, Wiesbaden, Germany); hepatitis B surface
antigen (AxSYM HbSAg V2 assay, Abbott Diagnostics);
hepatitis B surface and core antibodies (AxSYM Core 2.0,
Abbott Diagnostics); hepatitis C virus antibody (HCV,
AxSYM HCV Version 3.0), with serologic confirmation
of HCV-positive tests (Bio-Rad Monolisa anti-HCV Plus
Version 2, Bio-Rad Laboratories, Montreal, Quebec);
syphilis rapid plasma reagin (RPR, Pulse Diagnostic Inc,
Burlington, ON) and TPPA (Serodia TP.PA, Fujirebo
Inc). Neisseria gonorrhoeae and Chlamydia trachomatis
were detected in urine by nucleic acid amplification
testing (ProbeTec™ ET Amplified DNA Assay, Becton
Dickinson, Franklin Lakes, NJ, USA). Bacterial vaginosis
(BV) was diagnosed by the Nugent criteria using the re-
sults from a Gram stain smear of the vaginal swab [16].
A score of zero to three was considered normal, four to
six was classified as abnormal vaginal flora (or intermedi-
ate), and seven to 10 was defined as BV. Trichomonas
vaginalis infection was detected with the PCR method-
ology as described by Caliendo et al. [17]. Prior to applying
this method for study samples, the sensitivity of this
published PCR assay was verified in-house with a panel of
known positive samples and lack of cross reactivity con-
firmed by testing against a panel of 40 common genito-
urinary bacterial species. As found by numerous other
studies such as Schewbke et al., molecular testing has
greater sensitivity than wet mount for clinically relevant
Trichomonas vaginalis detection [18]. Human papilloma
virus infection with either 13 high risk (HR) or five low
risk (LR) types was detected from the vaginal swab
with the HPV HR/LR HC2 test (Digene Corporation,
Gaithersberg, MD, USA). The HR/LR HC2 test detects
virus above 5,000 copies/ml by measuring a chemilumin-
escent signal (relative light units, RLU) upon hybridization
of probes for LR HPV (6, 11, 42, 43, 44) or HR HPV (16,
18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 68). We calculated
the ratio of RLU to establish the cutoff: specimens with
1.0 or greater were considered positive and below 1.0
negative. Participants were considered actively infected by
hepatitis B if HBsAg was present and ever infected if
HBsAg, anti-HBc or anti-HBs (if not vaccinated) were
detected.
Statistical analysis
The data from the ACASI questionnaire and the labora-
tory results were analyzed in SAS (Version 9.3, SAS, Cary,
NC). We examined the prevalence of STIs (and exact
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binomial 95% confidence intervals) of co-infections strati-
fied by HIV status. We also examined the correlates of
chlamydial genital infection; in univariate analysis, four
variables were significantly related to chlamydia. However,
quasi-complete separation occurred and maximum likeli-
hood estimates could not be obtained when multivariate
logistic regression was performed. Therefore, we used a
series of four PROC FREQ procedures with the Cochran-
Mantel-Haenszel option. In this approach, each variable
was used as the predictor and the remaining three vari-
ables were used as stratifying, or controlling, variables.
Results
Study population
417 women (126 HIV-positive and 291 HIV-negative)
were included in the analysis. Their demographic charac-
teristics are shown in Table 1. HIV-negative women were
younger and more likely to be single than HIV-positive
women. Also, significantly more HIV-positive women
were born in Africa (81.0%) than HIV-negative women
(36.4%). The majority (59.5%) of HIV-positive women
were refugee claimants, higher than in HIV-negative
women (36.4%).
Bacterial infections
The prevalence of bacterial STIs among HIV-positive and
HIV-negative women is summarized in Table 2. Chlamydia,
gonorrhea and syphilis were infrequent. Only chlamydial
infection prevalence differed by HIV status, being higher
in HIV-negative women. BV was found in 15.4% of HIV-
positive women, similar to the 17.3% among HIV-negative
women.
Viral infections
The results of serologic testing for viral STIs are also
shown in Table 2. All viral pathogens were more prevalent
in HIV-positive women and most differences were statisti-
cally significant.
Vaginal HPV infection (either HR or LR) was detected
in 50.8% of HIV-positive and 22.6% of HIV-negative
women (p < 0.0001). Specifically, HR HPV infection was
more frequent in HIV-positive women (48.4% vs. 17.3%,
p < 0.0001) and the prevalence of LR HPV infection was
also higher (26.6% vs. 9.2%, p < 0.0001). HSV-2 infection
was markedly more frequent in HIV-positive (86.3%)
than HIV-negative (46.6%) women (p < 0.0001).
47.6% of HIV-positive women had serologic evidence
of HBV infection versus 21.2% of HIV-negative women.
Active HBV infection were also more common in HIV-
positive women (4.8% vs. 0.34%, p = 0.004). 66.1% of
HIV-positive compared to 44.0% of HIV-negative
women reported having been vaccinated against HBV
(p = 0.0001). Among those vaccinated in whom the num-
ber of doses was known, 58.3% (35/60) HIV-positive and
60.0% (54/90) HIV-negative women received only one or
two doses.
We also compared the prevalence of viral infections
between African and Caribbean women. While prior HBV
infection was more common in African women, both
HIV-positive (52.9% vs. 23.8%, p = 0.015) and HIV-
negative (33.3% vs. 17.1%, p = 0.004), no significant
differences were seen in the other viral infections.
Covariates of chlamydial infection
The prevalence of chlamydia among HIV-negative women
varied by age in years: 15–19, 8.7%; 20–24, 11.5%; 25–29,
3.8%; 30–34, 2.4%; and 35+, 0.0%. The results of the cor-
relation analysis of chlamydia are presented in Table 3.
Among HIV-negative women, the prevalence of chlamydia
was higher in younger (10.7% in those 15–24 years old
compared to 1.4% in those ≥ 25 years old, p = 0.0013) and
sexually active women (5.5% in those had had sex in the
previous six months compared to 0.0% in those had not,
p = 0.015). Chlamydia was more common in women born
in Canada (8.3%) than in Africa (1.0%), (p = 0.03). After
controlling for other variables indicated in Table 4, chla-
mydial infection was associated with sex in the previous
six months (p = 0.024) and younger age (p = 0.059). After
controlling for age, sexual behaviour and region of birth,
chlamydia was not significantly associated with HIV
status.
Covariates of bacterial vaginosis
BV was not associated with HIV status but was associated
with younger age in both HIV-positive and HIV-negative
women. Among HIV-positive women, the prevalence of
BV varied by age (in years): 15–24, 50.0% (1/2); 25–44,
21.2% (18/67); and 45+, 0.0% (0/36) (p for trend = 0.005).
The same trend of decreasing BV prevalence by age was
observed among HIV-negative women: 15–24, 27.0%;
25–44, 13.2%; and 45+, 15.5% (p for trend = 0.034).
HIV-negative women reporting sex in the previous six
months had a higher prevalence of BV (23.5%) than
those who did not (10.2%), (p = 0.008).
Discussion
The African and Caribbean communities in Ontario are
disproportionately affected by HIV but, until now, little
was known about the prevalence of other STIs which
may be important in HIV acquisition and progression. In
our study, we recruited women on the basis of HIV sta-
tus since our goal was not to assess prevalence of HIV,
but rather the relationship of co-infections with HIV in
this population. We found that classical sexually trans-
mitted infections, i.e. gonorrhea, chlamydia and syphilis,
were infrequent. BV was less common than expected
and the prevalence did not vary by HIV status. However,
persistent (or potentially persistent) viral infections
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were more frequent in African-Caribbean women in
general, particularly in HIV-positive women, with the
prevalence of herpes, HPV and CMV being much higher
than described in other Canadian populations [19-21].
While our study cannot demonstrate the causal direc-
tion of these associations, both HSV-2 and HPV have
been found to increase HIV susceptibility [2,4], implying
that education and other interventions, including HPV
Table 1 Demographic characteristics among HIV-positive and HIV-negative African-Caribbean women in Toronto
HIV-positive HIV-negative p value
Total participants 126 291
Age (years)
Mean 40.3 33.9 <0.0001a
Median (IQR) 40 (34-46) 31 (24-42)
15-24 2 (1.6%) 78 (26.8%)
25-34 30 (23.8%) 96 (33.0%)
35-44 58 (46.0%) 59 (20.3%)
45+ 36 (28.6%) 58 (19.9%)
Education
No education 4 (3.2%) 7 (2.4%) NS
Some/completed elementary school 11 (8.8%) 31 (10.7%)
Some/completed secondary school 46 (36.8%) 118 (40.8%)
Some/completed college/university 61 (48.8%) 119 (41.2%)
Some/completed graduate education 3 (2.4%) 14 (4.8%)
Marital status
Married/common-low 22 (18.0%) 72 (25.4%) <0.0001
Separated/divorced/widowed 57 (46.7%) 49 (17.3%)
Single 43 (35.2%) 163 (57.4%)
Annual household income
Less $10,000 38 (35.2%) 102 (55.1%) <0.0001
$10,000 - $19,999 37 (34.3%) 29 (15.7%)
$20,000 - $49,999 30 (27.8%) 34 (18.4%)
$50,000 or more 3 (2.8%) 20 (10.8%)
Language spoken
N 118 278
English 103 (87.3%) 252 (90.3%) NS
French 15 (12.7%) 32 (11.5%) NS
Spanish 0 (0.0%) 3 (1.1%) NS
Other 44 (37.3%) 49 (17.6%) <0.0001
Region of birth
Africa 102 (81.0%) 106 (36.4%) <0.0001b
Caribbean 21 (16.7%) 131 (45.0%)
Canada 2 (1.6%) 50 (17.2%)
Other 1 (0.8%) 4 (1.4%)
Immigration status at first arrival in Canada
Landed/permanent resident 25 (20.7%) 58 (25.1%) 0.0008b
Refugee claimant 72 (59.5%) 84 (36.4%)
Temporary worker 1 (0.8%) 3 (1.3%)
Visitor 17 (14.0%) 71 (30.7%)
Student 2 (1.7%) 6 (2.6%)
Non-status 4 (3.3%) 9 (3.9%)
aWilcoxon Rank Sum Test.
bFisher’s Exact Test.
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Table 3 Prevalence of chlamydia and predicting factors among HIV-positive and HIV-negative African-Caribbean
women in Toronto
HIV-positive HIV-negative Total
N % chlamydia N % chlamydia N % chlamydia
123 0.0% 286 3.8% 409 2.7%
Age (years)
15-24 2 0.0% 75 10.7% 77 10.4%
≥ 25 121 0.0% 211 1.4% 332 0.90%
p value 0.0013a <0.0001a
CMHb controlling for HIV status: p value 0.0014
Had sex in previous 6 months
Yes 58 0.0% 163 5.5% 221 4.1%
No 62 0.0% 100 0.0% 162 0.0%
p value 0.015a 0.012a
CMH controlling for HIV status: p value 0.017
Region of birth
Canada 2 0.0% 48 8.3% 50 8.0%
Caribbean 20 0.0% 129 4.7% 149 4.0%
Africa 100 0.0% 105 1.0% 205 0.5%
Other 1 0.0% 4 0.0% 5 0.0%
p value 0.13a 0.012a
CMH controlling for HIV status: p value 0.15
aFisher’s Exact Test.
bCochran-Mantel-Haenzel test.
Table 2 Prevalence of bacterial and viral pathogens among HIV-positive and HIV-negative African-Caribbean women in
Toronto
HIV-positive HIV-negative p value
Tested Positive Prevalence %
(95% CIa)
Tested Positive Prevalence %
(95% CI)
Chlamydia 123 0 0.0% (0.0-2.9% 286 11 3.8% (1.9-6.8%) 0.039b
Gonorrhea 124 0 0.0% (0.0-2.9%) 285 0 0.0% (0.0-1.3%) NS
Syphilis 126 1 0.79% (0.02-4.3%) 291 1 0.34% (0.01-1.9%) NS
Bacterial vaginosis 123 19 15.4% (9.6-23.1%) 283 49 17.3% (13.1-22.2%) NS
Abnormal vaginal flora 123 42 34.1% (25.8-43.2%) 283 84 29.7% (24.4-35.4%) NS
Trichomonas vaginalis 124 9 7.3% (3.4-13.3%) 286 13 4.5% (2.4-7.6%) NS
Yeast 123 9 7.3% (3.3-13.4%) 283 19 6.7% (4.1-10.3%) NS
HSV-1 123 111 90.2% (83.6-94.6%) 290 254 87.6% (83.2-91.2%) NS
HSV-2 124 107 86.3% (79.0-91.8%) 290 135 46.6% (40.7-52.5%) <0.0001
Cytomegalovirus 126 125 99.2% (95.7-100%) 291 274 94.2% (90.8-96.6%) 0.018
High risk HPV, vaginal 124 60 48.4% (39.3-57.5% 283 49 17.3% (12.9-21.7% <0.0001
HCV 126 5 4.0% (1.3-9.0%) 290 4 1.4% (0.38-3.5%) NS
HBV infectedc 126 6 4.8% (1.8-10.1%) 291 1 0.34% (0.01-1.9%) 0.004b
HBV everd 126 60 47.6% (38.7-56.7%) 283 60 21.2% (16.6-26.4%) <0.0001
HBV vaccination 109 72 66.1% (56.4-74.9%) 248 109 44.0% (37.7-50.4%) 0.0001
a95% exact binomial confidence interval.
bFisher’s Exact Test.
cInfected with HBV: HBsAg, with or without other HBV markers.
dEver infected with HBV: HBsAg, anti-HBc, or anti-HBs if not vaccinated for HBV.
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vaccination, might both reduce the high viral STI bur-
den and reduce HIV transmission in these communities.
Currently, quadrivalent HPV vaccine (Gardasil) is offered
free of charge to Grade 8 students in a school-based public
health program in Ontario. Many high-risk types of HPV
not infrequent in the population studied here (data not
shown) are not included in the present vaccine. Includ-
ing several of these in an expanded vaccine would be
desirable.
HBV infection was prevalent in both HIV-positive and
HIV-negative African-Caribbean women though HBV
vaccination rates were suboptimal in both groups. HBV
vaccine is safe, effective and cost-effective and efforts
should be made to reinforce HBV vaccination to protect
African-Caribbean women against this serious infection.
Our finding of a low prevalence of most bacterial STI
pathogens suggests that they may not play a major role
in HIV transmission in the African and Caribbean com-
munities in Toronto. However, given the availability of
effective antibiotic treatment for these pathogens and
the fact that many of these infections resolve without
treatment, the current status of participants may not re-
flect past infections. Thus, these pathogens could still have
played a role in HIV acquisition, especially since HIV-
positive women could have been infected before arriving
in Canada [22].
Interestingly, we found a significantly higher preva-
lence of chlamydial infection in HIV-negative compared
to HIV-positive women. This was due to younger age
and more frequent sex rather than HIV status and we
observed no association of chlamydia with HIV positivity
after adjusting for age and sexual behaviour [23]. The rate
of the chlamydial infection among HIV-negative women
was significantly higher among women under 25 years;
likely due to both increased sexual activity and the greater
biologic susceptibility. This suggests that there is room for
more systematic chlamydial screening in this population.
At this prevalence, chlamydial screening in this population
is probably cost-beneficial [24,25].
The low prevalence of BV was unexpected, as was the
lack of association with HIV status. BV has been associ-
ated with HIV transmission, both with HIV acquisition
in women [26] and with HIV transmission to male part-
ners of HIV-positive women [27]. Furthermore, previ-
ous studies have found that women of African and
Caribbean descent have an increased prevalence of BV,
whether residing in Africa [28] or in North America
[29] and that BV is more prevalent in HIV-positive
women [30]. In our study, the prevalence of BV in both
groups was less than 20%, slightly lower than the 23%
observed in white women in the USA, and much lower
than the 52% in African-American women in the same
study [29]. The reason for the low BV prevalence is not
clear, but may relate to the recruitment of women from
a clinic-based setting where treatment of common genital
infections was available.
While bacterial co-infections were not common, viral
STIs were prevalent and strongly associated with HIV
status. The prevalence of vaginal HPV (any type) of
22.6% we observed in HIV-negative women was almost
double the global average of 11.7% [31] and the 12.7% in
Ontario [31], but very similar to the pooled average of
24% reported in women in sub-Saharan Africa [10]. As
expected, the prevalence of vaginal HPV infection in
HIV-positive women was more than double than that of
their HIV-negative counterparts. In particular, we found
Table 4 Correlates of chlamydial infection, univariate and multivariatea
Chlamydia-positive Chlamydia-negative Chlamydia-prevalence p valueb Adjusted p valuec
HIV status
HIV-positive 0 120 0.0% 0.062 0.25
HIV-negative 9 254 3.4%
Age (years)
15-24 6 69 8.0% 0.002 0.059
≥ 25 3 305 0.97%
Had sex in previous 6 months
Yes 9 212 4.1% 0.012 0.024
No 0 162 0.0%
Region of birth
Canada 4 45 8.2% 0.018 0.48
Caribbean 4 132 2.9%
Africa 1 192 0.52%
Other 0 5 0.0%
aAmong 383 participants with all data for the variables above.
bFisher’s Exact Test.
cCochran-Mantel-Haenszel controlling other variables in the table.
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a strong association of HPV and oncogenic HR HPV
with HIV infection status and, among HIV-positive
women, the majority of HPV infections were HR strains.
While we cannot ascertain whether these HR HPV in-
fections are persistent given the cross-sectional design,
our findings reinforce the need for regular cervical can-
cer screening in this population. Furthermore, we used
HybirdCapture2 test to detect HPV DNA present at
5,000 copies or higher. Thus, it is possible that a small
subset of individuals might be infected by HPV and yet
shed HPV DNA at a level that is below the threshold of
detection. The frequency of such an occurrence is un-
known. Finally, participants self-sampled for all genital
diagnostics, i.e. using either urine or vaginal swabs, and
direct cervical samples were not obtained. Vaginal self-
sampling is considered a reliable surrogate for clinician
collected cervical sampling for HPV DNA detection [32].
We observed a prevalence of HSV-2 among HIV-
negative women of just under 50%, very similar to the 48%
seen in Black, non-Hispanic women in the US [13] but
well above the general population prevalence of 21% or
less in women in both the US [13] and Ontario [21]. A re-
cent systematic survey of the health of Canadians carried
out in 2009–2011 found a weighted prevalence of HSV-2
of 16.1% in women aged 14 to 59 years [33]. As with pre-
vious studies, we found that HSV-2 infection was very
strongly associated with HIV infection. It should be noted
that the positive predictive value (PPV) of the Focus
HSV2 ELISA test may be poor in populations with a low
prevalence of HSV-2, at just 38% in a student population
with an HSV-2 prevalence of under 4% [34]. However, the
PPV was over 93% in a population with a higher HSV-2
prevalence of over 40% [35]. Therefore, we believe that the
high HSV-2 prevalence in our participants (48% in the
HIV-uninfected women) means that this is less likely to be
a concern in our study.
Our cross-sectional study format does not allow us to
assess the temporal nature of the relationship between
HIV and these viral infections, i.e. whether HPV and
HSV-2 infection were acquired before or after HIV in-
fection. It is well established that HSV-2 increases HIV
susceptibility [36], while the reverse association is not
clear. Furthermore, a strong age association of HSV-2
infection was seen in the HIV-negative participants in
our study (data not shown) but this was not apparent in
HIV-positive women. Therefore, it is plausible that pre-
ceding HSV-2 infection led to enhanced HIV acquisition
after subsequent sexual exposure, resulting in a high
HSV-2 prevalence in all ages of HIV-positive women.
While vaginal HPV infection may also enhance HIV
susceptibility [37], HIV infection is known to increase
both the incidence and duration of subsequent HPV in-
fection [38], making it harder to hypothesize regarding
the temporal nature of this association.
Participants were recruited from a community health
centre in downtown Toronto. Thus, subjects may not
be representative of African-Caribbean population in
Toronto. However, they do represent a broad sample of
women by age, region of birth, and education, Further-
more the distribution by these variables is very similar to
that of African- and Caribbean-born women in Toronto
according to the 2006 Canada Census (data not shown).
We were unable to recruit our initial target of 300 HIV-
positive women. Nevertheless, the number recruited
provided sufficient power to compare these populations
for most of the variables of interest. As in all studies of
this type, the information on sexual behaviour was self-
reported and therefore subject to inaccuracy and poten-
tial bias. In general, women may be less likely to report
risky sexual behaviours, especially if they are perceived
as socially undesirable given the pervasive information
promoting condom use.
Conclusions
Overall, our study found that classical STIs were infre-
quent in women from the African and Caribbean com-
munity in Toronto, Canada, implying that enhanced
screening and treatment is not likely to reduce HIV
transmission, with the possible exception of chlamydial
infection in younger women. However, persistent, or
potentially persistent, HSV-2 and HPV viral infections
were much more prevalent than in the general population
in Ontario, emphasizing the vulnerability of African and
Caribbean women to HIV infection and the need to effect-
ively reduce their exposure to HIV.
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